JPMorgan analyst Anupam Rama lowered the firm’s price target on Solid Biosciences (SLDB) to $12 from $15 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
Questions or Comments about the article? Write to editor@tipranks.com